Indications

In the treatment of non-small cell lung cancer (NSCLC), combined with NP, MVP chemotherapy, this product can be tried in ineffective therapy for advanced or recurrent NSCLC patients with other methods. 

Highlights：

1. Promoting the concentration of chemotherapeutic drugs in tumor by four to six times

2. Owning synergistic effect by combining various chemotherapeutics

3. Promoting chemotherapeutic effect of late NSCLC and NHL significantly

4. Efficacy of Monotherapy in Malignant pleural effusion and ascites: 87%  

5. Launching time in China: 2004

6. International similar drug: Beromun，Tasonermin®  by Boehringer Ingelbeim 

Dosage Form

Lyophilized powder for injection

Specification

500000 IU/ vial 

In the treatment of non-Hodgkin's lymphoma (NHL), combined therapy with BACOP chemotherapy, also can be used in trial by chemotherapy or other methods in the treatment of advanced NHL of invalid patients.